Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Erratum: Effect of low molecular weight heparin and ulinastatin as a combined therapy on soluble myeloid cell expression and intestinal mucosal function in patients with severe pancreatitis

Dong Qian , Xinyuan Luan, Yanan Zhang

The Third Department of Hepatobiliary and Pancreatic Diseases, Nankai Hospital, Tianjin 300100, China;

For correspondence:- Dong Qian Email: NKYYLXY@163.com

Accepted: 7 June 2022 Published: 30 November 2022

Citation: Qian D, Luan X, Zhang Y. Erratum: Effect of low molecular weight heparin and ulinastatin as a combined therapy on soluble myeloid cell expression and intestinal mucosal function in patients with severe pancreatitis. Trop J Pharm Res 2022; 21(11):2493-2493 doi: 10.4314/tjpr.v21i11.32

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

In the earlier published article, the ethical approval number of the Methods’ section was wrongly provided by the authors. The correct approval number should be: NKYY_YWKT_IRB_2021_009_01.

New citation: Qian D, Luan X, Zhang Y. Effect of low molecular weight heparin and ulinastatin as a combined therapy on soluble myeloid cell expression and intestinal mucosal function in patients with severe pancreatitis. Trop J Pharm Res 2022; 21(7):1515-1521 doi: 10.4314/tjpr.v21i7.23

Erratum: 2022; 21(11): 2493 doi: http://dx.doi.org/10.4314/tjpr.v 21i11.32

Earlier citation: Qian D, Luan X, Zhang Y. Effect of low molecular weight heparin and ulinastatin as a combined therapy on soluble myeloid cell expression and intestinal mucosal function in patients with severe pancreatitis. Trop J Pharm Res 2022; 21(7):1515-1521 doi: 10.4314/tjpr.v21i7.23

Keywords: Heparin, ulinastatin, myeloid cell expression, intestinal mucosal function, severe pancreatitis